oncogenes/growth factors & environment 2006/thyroid/clark1.pdf · microsoft powerpoint - clark1...
TRANSCRIPT
![Page 1: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/1.jpg)
8th Postgraduate Course in Endocrine Surgery
Crete, GreeceSeptember, 2006
Orlo H. Clark M.D.
Oncogenes/Growth Factors & Environment
![Page 2: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/2.jpg)
Thyroid Cancer
Thyroid cancer is the 8Thyroid cancer is the 8thth most common and most common and most rapidly increasing cancer in womenmost rapidly increasing cancer in womenAn estimated 30,000 cases will occur in the An estimated 30,000 cases will occur in the United States in 2006United States in 2006It frequently affects individuals under 50 It frequently affects individuals under 50 years of ageyears of ageThere are about 300,000 survivors of There are about 300,000 survivors of thyroid cancer in the USAthyroid cancer in the USA
![Page 3: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/3.jpg)
Thyroid CancerThere are 5 major types of thyroid There are 5 major types of thyroid cancers: (Papillary 80% / Follicular cancers: (Papillary 80% / Follicular 9% / Hurthle Cell 3% / Medullary 9% / Hurthle Cell 3% / Medullary 7% / Anaplastic 1%)7% / Anaplastic 1%)Familial thyroid cancer occurs in Familial thyroid cancer occurs in about 25% of patients with about 25% of patients with medullary thyroid cancer and 5 % of medullary thyroid cancer and 5 % of those with papillary and Hurthle cell those with papillary and Hurthle cell cancercancerFamilial Non Medullary thyroid Familial Non Medullary thyroid cancer is defined as thyroid cancer cancer is defined as thyroid cancer affecting at least two first degree affecting at least two first degree relatives (roughly 90% are papillary)relatives (roughly 90% are papillary)
![Page 4: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/4.jpg)
Thyroid Cancer Epidemiology
Ron et al (1991): 5 fold increased risk of Ron et al (1991): 5 fold increased risk of thyroid cancer when another family member thyroid cancer when another family member has thyroid cancer has thyroid cancer
Goldgar et al. (1994): 9 fold increase of Goldgar et al. (1994): 9 fold increase of thyroid cancer in association with breast thyroid cancer in association with breast cancercancer
![Page 5: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/5.jpg)
Environment and Genetics
GeneticsGenetics EnvironmentEnvironment
DiseaseDisease
![Page 6: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/6.jpg)
Histogram – Occult PTC
![Page 7: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/7.jpg)
Patient with large PTC
![Page 8: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/8.jpg)
CT of PTC
![Page 9: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/9.jpg)
PET Scan
![Page 10: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/10.jpg)
Thyroid Cancer: A Lethal Endocrine Neoplasm
(NIH Conference)
Although the mortality rate from Although the mortality rate from thyroid cancer is low, it is the thyroid cancer is low, it is the highest among cancers affecting highest among cancers affecting the endocrine glands (excluding the endocrine glands (excluding the ovary).the ovary).
(Robbin J et al. (Robbin J et al. Ann Intern MedAnn Intern Med 115:133115:133--147, 1991)147, 1991)
![Page 11: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/11.jpg)
Death from Thyroid CancerUCSF 1965-1995
Patient Characteristics (102 patients)
Mean age 58 years (range 12 to 90 years)31 less than 45 years of ageTumor size ranged from 0.6 to 13.0 cmsMetastases in 46% (regional) and 18% distant
50% of patients with PTC & HTC verses11% of FTC died of locally advanced disease
(Wu HS et al, JACS 191:600-606, 2000)
![Page 12: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/12.jpg)
Genes Implicated in Sporadic Papillary Thyroid Cancer
Dedifferentiated or undifferentiated tumorsDedifferentiated or undifferentiated tumorsp53p53
Over expressed Tyrosine KinaseOver expressed Tyrosine KinaseMETMET
Activated in about 15% of PTC (Tyrosine Kinase) Activated in about 15% of PTC (Tyrosine Kinase) TRKTRK
Early in tumor development and more frequent in Early in tumor development and more frequent in follicular thyroid cancer follicular thyroid cancer
rasras
Most common mutation in PTCMost common mutation in PTC-- Appears to be Appears to be associated with more aggressive tumorsassociated with more aggressive tumors
BRAFBRAF
More frequent in children and after radiation More frequent in children and after radiation (Tyrosine Kinase)(Tyrosine Kinase)
RET/PTCRET/PTC
Comment Comment GeneGene
![Page 13: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/13.jpg)
Normal follicular thyroid
cell
Hyperfunctioning thyroid nodule
Occult PTC
PTCPoorly
differentiated PTC
Anaplastic Thyroid Cancer
Follicular Adenoma
FTC
Hürthle Cell Adenoma
HCC
rasTRK
RET/PTCMETmyc
BRAFras
PTENfos
PAX8 / PPARγ
rasmyc
fosp53
p53
p53
TSH-RGsα/gsp
Normal parafollicular
C-cell C-cellhyperplasiaRET
MTC
![Page 14: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/14.jpg)
Inherited Thyroid Cancer Syndromes
* > 80% of these thyroid cancers have ret/PTC somatic mutations.* > 80% of these thyroid cancers have ret/PTC somatic mutations.
PTE NPTE N10q23.310q23.3Cowden's SyndromeCowden's Syndrome
APC*APC*5q215q21--2222Familial adenomatous Familial adenomatous polyposispolyposis
??2q212q21PTC PTC –– Follicular Follicular variant PTCvariant PTC
??1q 211q 21PTCPTC--Renal neoplasiaRenal neoplasia
??19p 13.219p 13.2Trabecular, oxyphilic Trabecular, oxyphilic & MNG& MNG
??14q3114q31Multinodular goiterMultinodular goiter(MNG)(MNG)
GeneGeneChromosome Chromosome LocationLocation
SyndromeSyndrome
![Page 15: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/15.jpg)
Familial Non-Medullary Thyroid Cancer• Familial Hürthle cell (TCO): 19p13.21
• Familial papillary thyroid cancer with papillary renal neoplasia (fPTC/PRN): 1q212
• Familial papillary thyroid cancer in Tas1 (fPTC): 2q213
fPTC/PRN
fPTC
TCO
1. Canzian et al. Am J Hum Genet. 63:1743, 1998. 2. Malchoff et al. JCEM. 85(5):1758, 2000.3. McKay et al. Am J Hum Genet. 69(2):440, 2001
![Page 16: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/16.jpg)
Photo of Thyroid Cancer Cell
![Page 17: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/17.jpg)
![Page 18: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/18.jpg)
TSH Suppression and Thyroid Cancer
“After 30 years’ follow“After 30 years’ follow--up, we found that up, we found that there were 25% fewer recurrences in there were 25% fewer recurrences in
patients treated with Tpatients treated with T44 as compared with as compared with no adjunctive therapy (p no adjunctive therapy (p < < .01), and there .01), and there were fewer cancer deaths in the Twere fewer cancer deaths in the T4 4 group group
(6% versus 12%; p (6% versus 12%; p < 0.0001).< 0.0001).””
(Mazzaferri EL, Jhiang, SM: (Mazzaferri EL, Jhiang, SM: Am J MedAm J Med 73:424, 1994)73:424, 1994)
![Page 19: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/19.jpg)
TSH Suppression and Thyroid Cancer
RelapseRelapse--free survival was longer in patients free survival was longer in patients with TSH with TSH <0.05 or < 0.1 than in those with <0.05 or < 0.1 than in those with nonnon--suppressed TSH valuessuppressed TSH values
The level of TSH suppression was an The level of TSH suppression was an independent prognostic factor using independent prognostic factor using multivariate analysis multivariate analysis
(Pujol P, et al. (Pujol P, et al. JCEMJCEM, 1996), 1996)
![Page 20: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/20.jpg)
Outcome of Children Treated for Thyroid Cancer
“Thyroid stimulating hormone suppression “Thyroid stimulating hormone suppression was the only intervention shown to reduce was the only intervention shown to reduce
the recurrence rate.” the recurrence rate.”
(Landau D (Landau D et alet al European J CancerEuropean J Cancer 36: 21436: 214--220, 2000)220, 2000)
![Page 21: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/21.jpg)
Thyroid Cancer
ret PTC (Tg ret PTC (Tg -- PTC PTC -- 1) transgenic mice1) transgenic mice
develop thyroid cancerdevelop thyroid cancerare responsive to TSH suppression are responsive to TSH suppression (grow slower but still grow) (grow slower but still grow)
(S. Jhiang, PhD (S. Jhiang, PhD –– ATAATA, 2002), 2002)
![Page 22: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/22.jpg)
![Page 23: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/23.jpg)
![Page 24: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/24.jpg)
![Page 25: Oncogenes/Growth Factors & Environment 2006/thyroid/Clark1.pdf · Microsoft PowerPoint - Clark1 Author: Bracht Created Date: 10/11/2006 9:15:09 AM](https://reader035.vdocument.in/reader035/viewer/2022071009/5fc71743196f593052745018/html5/thumbnails/25.jpg)
Thyroid Cancer: Potential New Methods of Therapy
AntiAnti--angiogenesis agentsangiogenesis agentsRedifferentiation agentsRedifferentiation agents
RetinoidsRetinoidsAromatic fatty acids (phenylacetate/phenylbutrate)Aromatic fatty acids (phenylacetate/phenylbutrate)PPAR gamma agonistsPPAR gamma agonistsHistone deacetylase (HDAC) inhibitors (Tricostatin Histone deacetylase (HDAC) inhibitors (Tricostatin A/Depsipeptide)A/Depsipeptide)COX 2 inhibitorsCOX 2 inhibitors
Gene therapyGene therapyP53/TTFP53/TTF11/PAX8/NIS/PAX8/NIS
Anti invasion (metalloproteinase inhibitorsAnti invasion (metalloproteinase inhibitors